PDUFA Formula Could Better Incorporate Present Economic Conditions
Executive Summary
FDA may give up some consistency in its user fee inflation formula, making it more beholden to the short-term whims of the U.S. economy.
You may also be interested in...
GDUFA III Calculation Faces Rising Staff Costs
After dialing back the inflation adjustment in GDUFA II, FDA’s ANDA review program now faces rising personnel costs, in contrast to the agency overall, suggesting that GDUFA III might need a more tailored formula.
Generic Drug User Fee Projections Complicated By Shifting Personnel Costs
After dialing back the inflation adjustment in GDUFA II, FDA’s ANDA review program now faces rising personnel costs, in contrast to the agency overall, suggesting that GDUFA III might need a more tailored formula.
FDA Drug Review Costs Rise, But Personnel Spending Flattens
Less than 60% of the total spending on reviews was attributed to employee compensation and benefits in FY 2011. FDA says it is normal, but the figure is lower than costs seen in recent years.